Background Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disease,
and among the non-invasive tests, controlled attenuation parameter (CAP) and liver stiffness …

Ligand-activated nuclear receptors, including peroxisome proliferator-activated receptor
alpha (PPARα), pregnane X receptor, and constitutive androstane receptor, were first …

Colorectal cancer (CRC) is one of the most commonly diagnosed cancers, and it is
characterized by genetic and epigenetic alterations, as well as by inflammatory cell …

Non-alcoholic fatty liver disease (NAFLD) is a major chronic liver disease that can lead to
liver cirrhosis, liver cancer, and ultimately death. NAFLD is pathologically classified as non …

The purpose of our study was to evaluate the diagnostic accuracy of the ultrasound-guided
attenuation parameter (UGAP) for the detection of hepatic steatosis in comparison with the …

Background Few studies have evaluated both liver fibrosis and steatosis in patients with
nonalcoholic fatty liver disease (NAFLD) using both FibroScan® M and XL probes. This …

Background Concomitant chronic hepatitis B infection (CHB) and non-alcoholic fatty liver
disease (NAFLD) is common, but the implications of NAFLD on clinical outcomes of CHB …

AIM The impact of mild drinking habit (less than 20 g/d of ethanol) on the clinical course of
non-alcoholic fatty liver disease (NAFLD) has not been determined. We examined the …

Nonalcoholic fatty liver disease (NAFLD) ranges from simple steatosis to NAFLD-related
liver cirrhosis and is a main cause of chronic liver diseases. Patients with nonalcoholic …

Background Controlled attenuation parameter (CAP) is a recently introduced, non-invasive
and quantitative method to evaluate hepatic steatosis demonstrated in adults, but limited in …